A clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to transform medicine and improve patient outcomes. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
Lead Underwriter
BofA Securities, Inc, Canaccord Genuity LLC, Cantor Fitzgerald & Co., Stifel Nicolaus & Company, Incorporated
